NFE2L2 and cystic fibrosis: Borcherding et al. demonstrated that the CFTR modulators VX-809 (Lumacaftor) and VX-661 (Tezacaftor) significantly increase Nrf2 activity in CF patients [31]; this could represent one of the mechanisms through which CFTR modulators mitigate the inflammatory response and oxidative stress.